S&P 500 Futures
(0.60%) 5 076.75 points
Dow Jones Futures
(0.34%) 38 197 points
Nasdaq Futures
(0.83%) 17 584 points
Oil
(0.76%) $79.60
Gas
(2.38%) $1.978
Gold
(-0.14%) $2 307.70
Silver
(-0.91%) $26.51
Platinum
(0.62%) $960.80
USD/EUR
(0.18%) $0.935
USD/NOK
(0.54%) $11.09
USD/GBP
(0.08%) $0.799
USD/RUB
(-1.52%) $91.84

Echtzeitaktualisierungen für Dermapharm Holding SE [DMP.DE]

Börse: XETRA Sektor: Pharmaceuticals Industrie: Drug Manufacturers—Specialty & Generic
Zuletzt aktualisiert2 Mai 2024 @ 11:33

0.32% 31.50

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 11:33):

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts...

Stats
Tagesvolumen 3 975.00
Durchschnittsvolumen 21 033.00
Marktkapitalisierung 1.70B
EPS €0 ( 2024-03-27 )
Nächstes Ertragsdatum ( €0 ) 2024-05-15
Last Dividend €1.050 ( 2023-06-15 )
Next Dividend €0 ( N/A )
P/E 27.16
ATR14 €0.105 (0.33%)

Dermapharm Holding SE Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Dermapharm Holding SE Finanzdaten

Annual 2022
Umsatz: €1.02B
Bruttogewinn: €660.83M (64.49 %)
EPS: €2.49
FY 2022
Umsatz: €1.02B
Bruttogewinn: €660.83M (64.49 %)
EPS: €2.49
FY 2021
Umsatz: €942.91M
Bruttogewinn: €620.69M (65.83 %)
EPS: €3.89
FY 2020
Umsatz: €793.83M
Bruttogewinn: €463.48M (58.39 %)
EPS: €1.590

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€1.050
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.59 - Stable (11.70%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.770 2019-06-05
Last Dividend €1.050 2023-06-15
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 5 --
Total Paid Out €5.67 --
Avg. Dividend % Per Year 0.00% --
Score 3 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.59
Div. Directional Score 8.18 --
Next Divdend (Est)
(2025-03-31)
€0.606 Estimate 3.09 %
Dividend Stability
0.25 Very Poor
Dividend Score
3.00
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
MTX.DE Ex Dividend Junior 2023-05-12 Annually 0 0.00%
4I1.DE Ex Dividend Knight 2023-09-26 Quarterly 0 0.00%
WSU.DE Ex Dividend Junior 2023-05-16 Annually 0 0.00%
FC9.DE Ex Dividend Junior 2023-06-14 Annually 0 0.00%
PCG6.F Ex Dividend Junior 2023-07-28 Quarterly 0 0.00%
AMG.DE Ex Dividend Knight 2023-08-17 Quarterly 0 0.00%
HBH.DE Ex Dividend Junior 2023-07-10 Annually 0 0.00%
SBS.DE Ex Dividend Junior 2023-05-18 Annually 0 0.00%
BYW6.DE Ex Dividend Junior 2023-06-07 Annually 0 0.00%
KEL.DE Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.08211.5008.3610.00[0 - 0.5]
returnOnAssetsTTM0.04401.2008.5310.00[0 - 0.3]
returnOnEquityTTM0.1741.5009.1710.00[0.1 - 1]
payoutRatioTTM0.595-1.0004.05-4.05[0 - 1]
currentRatioTTM1.8570.8005.724.57[1 - 3]
quickRatioTTM0.7980.800-0.0114-0.00913[0.8 - 2.5]
cashRatioTTM0.3471.5009.1810.00[0.2 - 2]
debtRatioTTM0.508-1.5001.539-2.31[0 - 0.6]
interestCoverageTTM4.321.0009.519.51[3 - 30]
operatingCashFlowPerShareTTM5.182.008.2710.00[0 - 30]
freeCashFlowPerShareTTM4.452.007.7710.00[0 - 20]
debtEquityRatioTTM2.01-1.5001.968-2.95[0 - 2.5]
grossProfitMarginTTM0.6421.0002.642.64[0.2 - 0.8]
operatingProfitMarginTTM0.1921.0008.158.15[0.1 - 0.6]
cashFlowToDebtRatioTTM0.2541.0009.709.70[0.2 - 2]
assetTurnoverTTM0.5360.8009.767.81[0.5 - 2]
Total Score10.77

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM17.801.0008.300[1 - 100]
returnOnEquityTTM0.1742.509.4710.00[0.1 - 1.5]
freeCashFlowPerShareTTM4.452.008.5210.00[0 - 30]
dividendYielPercentageTTM3.341.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM5.182.008.2710.00[0 - 30]
payoutRatioTTM0.5951.5004.05-4.05[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2411.0006.480[0.1 - 0.5]
Total Score5.59

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.